PURPOSE: A meta-analysis was conducted to estimate the prevalence of patients with molecularly confirmed Leber hereditary optic neuropathy (LHON) carrying any of the 3 primary mtDNA mutations (m.11778G>A, m.14484T>C, m.3460G>A) which cause this inherited form of blindness. METHODS: A literature search was conducted to identify primary reports with LHON prevalence data reported for Europe. The overall prevalence of LHON with molecularly confirmed diagnosis was evaluated by weighting the prevalence estimates of the individual studies by the inverse of their variance. RESULTS: Based on this meta-analysis of 5 European studies providing appropriate information, the estimated prevalence of LHON disease associated with the combined m.11778G>A, m.14484T>C, m.3460G>A mutations was ~1:45,000 (2.23 x 10(-5); 95% confidence interval [CI] 2.01-2.44 x 10(-5)). Patients with LHON carrying either the m.11778G>A or the m.3460G>A mutation have a more severe clinical presentation and a much lower chance of spontaneous recovery from vision loss compared to patients with the m.14484T>C mutation. The estimated prevalence for patients with LHON in Europe carrying either of these severe mutations (m.11778G>A or m.3460G>A) was ~1:65,000 (1.54 x 10(-5); 95% CI 1.33-1.74 x 10(-5)). CONCLUSIONS: Although this meta-analysis summarizes the existing prevalence data for the primary, disease-causing mitochondrial DNA mutations of LHON in Europe, there is still a clear lack of reliable primary epidemiologic data for this devastating ophthalmologic disease.
PURPOSE: A meta-analysis was conducted to estimate the prevalence of patients with molecularly confirmed Leber hereditary optic neuropathy (LHON) carrying any of the 3 primary mtDNA mutations (m.11778G>A, m.14484T>C, m.3460G>A) which cause this inherited form of blindness. METHODS: A literature search was conducted to identify primary reports with LHON prevalence data reported for Europe. The overall prevalence of LHON with molecularly confirmed diagnosis was evaluated by weighting the prevalence estimates of the individual studies by the inverse of their variance. RESULTS: Based on this meta-analysis of 5 European studies providing appropriate information, the estimated prevalence of LHON disease associated with the combined m.11778G>A, m.14484T>C, m.3460G>A mutations was ~1:45,000 (2.23 x 10(-5); 95% confidence interval [CI] 2.01-2.44 x 10(-5)). Patients with LHON carrying either the m.11778G>A or the m.3460G>A mutation have a more severe clinical presentation and a much lower chance of spontaneous recovery from vision loss compared to patients with the m.14484T>C mutation. The estimated prevalence for patients with LHON in Europe carrying either of these severe mutations (m.11778G>A or m.3460G>A) was ~1:65,000 (1.54 x 10(-5); 95% CI 1.33-1.74 x 10(-5)). CONCLUSIONS: Although this meta-analysis summarizes the existing prevalence data for the primary, disease-causing mitochondrial DNA mutations of LHON in Europe, there is still a clear lack of reliable primary epidemiologic data for this devastating ophthalmologic disease.
Authors: M Eckenweiler; C B Catarino; C Gallenmueller; T Klopstock; W A Lagrèze; R Korinthenberg; J Kirschner Journal: J Neurol Date: 2015-11-03 Impact factor: 4.849
Authors: Elena Starikovskaya; Sofia Shalaurova; Stanislav Dryomov; Azhar Nazhmidenova; Natalia Volodko; Igor Bychkov; Ilia Mazunin; Rem Sukernik Journal: Cells Date: 2019-12-04 Impact factor: 6.600
Authors: Madushani Dharmarwardana; André F Martins; Zhuo Chen; Philip M Palacios; Chance M Nowak; Raymond P Welch; Shaobo Li; Michael A Luzuriaga; Leonidas Bleris; Brad S Pierce; A Dean Sherry; Jeremiah J Gassensmith Journal: Mol Pharm Date: 2018-05-29 Impact factor: 4.939